A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: Ipatasertib
DRUG: Paclitaxel
DRUG: Placebo for Atezolizumab
DRUG: Placebo for Ipatasertib

Sponsor

Hoffmann-La Roche